News

Filter

Current filters:

Eprosartan Mesylate

1 to 9 of 39 results

Kos enters cardiovascular R&D alliance with Biovail

09-05-2005

US firm Kos Pharmaceuticals has entered into a strategic commercialization and R&D alliance with Canada's…

Cardizem LADiltiazemDiltiazem HclEnalaprilEprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableSolvayTevetenTeveten HCTTiazacVasotec

Biovail revises full-year outlook on robust sales

20-09-2004

Canadian drugmaker Biovail Corp has updated its revenue guidance for2004, narrowing its previous sales…

AcyclovirBupropion HclBupropion Hydrochloride Extended-ReleaseCardizem LADiltiazemEprosartan MesylateTevetenWellbutrinWellbutrin XLZoviraxZyban

FDA clears Biovail's Cardizem LA for the treatment of angina

12-04-2004

The US Food and Drug Administration has approved the use of Canada-based Biovail's hypertension drug,…

Cardizem LADiltiazemEprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableTevetenTeveten HCT

Novel promotion deal for Altana and Solvay

29-03-2004

Germany's Altana Pharma and Belgium-based Solvay have entered a novel co-promotion arrangement in the…

ALTANA PharmaEprosartan MesylateSolvayTeveten

Sales and profits down at Belgium's Solvay

11-08-2003

Belgium's Solvay has reported a 6% drop in profits to 3.79 billion euros ($4.36 billion) for the first…

Eprosartan MesylateSolvayTeveten

Biovail gets US OK for Teveten HCT

03-03-2003

Canada's Biovail Corp has been granted US approval to market Teveten HCT(eprosartan mesylate and hydrochlorothiazide)…

Eprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableSolvayTevetenTeveten HCT

Solvay pharma earnings grow 13%

17-02-2003

Belgium's Solvay Group reported pharmaceutical sales of 1.86 billioneuros ($2 billion), a rise of 5%…

Eprosartan MesylateSolvayTeveten

1 to 9 of 39 results

Back to top